Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab Adjuvant Therapy in Renal Cell Carcinoma
NCT03024996Phase 3Terminated
- Sponsor
- Roche
- Start
- Jan 2017
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 28
01
Overview
A Phase 3 trial of atezolizumab in renal cell carcinoma (RCC), sponsored by Roche. Started Jan 2017; status: terminated.
02
Drugs
atezolizumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03024996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03024996.